Pharmacologic treatment of heart failure.
An increased understanding of the pathophysiologic changes underlying CHF, advanced monitoring technology, and a wider array of drug therapy have improved the prognosis of patients with this disorder. These advances allow for greater individualization of therapy, improve patient compliance, and lower the incidence of undesirable side effects. Of course, with the increase in complexity of treatment choices comes the need for more knowledgeable practitioners who can select the most appropriate therapeutic approach. All practitioners also must make every effort to educate the patients about their disease, treatments, and necessary lifestyle changes so that optimal benefits can be realized.
Nagelhout
J J
JJ
College of Pharmacy, Wayne State University, Detroit, Michigan.
D002301:Cardiac Glycosides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004232:Diuretics / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy* / Q000451:nursing / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
D002301:Cardiac Glycosides; D002316:Cardiotonic Agents; D004232:Diuretics; D014665:Vasodilator Agents